MX2022001655A - Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). - Google Patents

Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Info

Publication number
MX2022001655A
MX2022001655A MX2022001655A MX2022001655A MX2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A
Authority
MX
Mexico
Prior art keywords
solid dispersions
sgc stimulator
relates
soxazol
fluorobenzyl
Prior art date
Application number
MX2022001655A
Other languages
English (en)
Inventor
Ahmad Hashash
Vasu Sethuraman
Craig Anthony Dunbar
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2022001655A publication Critical patent/MX2022001655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con dispersiones sólidas de 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobencil)-5-(iso xazol-3-il)-1H-pirazol-3-il)pirimidin-4-il)amino)metil)propan-2-o l amorfo (compuesto I) o una sal farmacéuticamente aceptable de estos. También se refiere a composiciones farmacéuticas y formas farmacéuticas unitarias de dosificación oral que las comprenden, y uso de estas. (ver Fórmula) Compuesto 1.
MX2022001655A 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). MX2022001655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US201662359440P 2016-07-07 2016-07-07

Publications (1)

Publication Number Publication Date
MX2022001655A true MX2022001655A (es) 2022-03-11

Family

ID=57590822

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022001655A MX2022001655A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Country Status (12)

Country Link
US (1) US20190269619A1 (es)
EP (1) EP3383372B1 (es)
JP (3) JP6952707B2 (es)
KR (1) KR20180086497A (es)
CN (4) CN116942616A (es)
AU (1) AU2016364976B2 (es)
BR (1) BR112018011154B1 (es)
CA (1) CA3006746C (es)
EA (1) EA201891315A1 (es)
IL (2) IL259493B (es)
MX (2) MX2022001655A (es)
WO (1) WO2017095697A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012001A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
CN109563077A (zh) * 2016-07-07 2019-04-02 铁木医药有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
MX2019000138A (es) * 2016-07-07 2019-06-10 Ironwood Pharmaceuticals Inc Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble.
WO2019055859A1 (en) 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
TW202402741A (zh) * 2018-01-10 2024-01-16 美商賽克瑞恩醫療公司 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
JP2020023472A (ja) * 2018-07-30 2020-02-13 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
WO2020027030A1 (en) * 2018-07-30 2020-02-06 Ricoh Company, Ltd. Method for producing particle, and particle produced by the method and medicament
US20230147869A1 (en) * 2019-09-23 2023-05-11 Bionomics Limited Therapeutic formulations and uses thereof
EP4051281A1 (en) 2019-10-29 2022-09-07 Cyclerion Therapeutics, Inc. Treatment of diabetic nephropathy with an sgc stimulator
WO2023009710A1 (en) 2021-07-28 2023-02-02 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
CN108912111B (zh) * 2013-03-15 2021-09-14 赛克里翁治疗有限公司 化合物及药用组合物
US20160324856A1 (en) * 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders

Also Published As

Publication number Publication date
IL290338A (en) 2022-04-01
CN108883071A (zh) 2018-11-23
EA201891315A1 (ru) 2018-12-28
BR112018011154A2 (pt) 2018-11-21
IL259493B (en) 2022-03-01
US20190269619A1 (en) 2019-09-05
CN116637076A (zh) 2023-08-25
IL290338B1 (en) 2023-01-01
EP3383372B1 (en) 2023-11-01
IL259493A (en) 2018-07-31
JP2022000464A (ja) 2022-01-04
CN116637077A (zh) 2023-08-25
AU2016364976A1 (en) 2018-06-14
IL290338B2 (en) 2023-05-01
EP3383372A1 (en) 2018-10-10
CA3006746C (en) 2024-01-30
KR20180086497A (ko) 2018-07-31
CA3006746A1 (en) 2017-06-08
WO2017095697A1 (en) 2017-06-08
CN116942616A (zh) 2023-10-27
JP6952707B2 (ja) 2021-10-20
JP2023100851A (ja) 2023-07-19
BR112018011154B1 (pt) 2023-09-26
MX2022001656A (es) 2022-03-11
JP2019501216A (ja) 2019-01-17
JP7277534B2 (ja) 2023-05-19
AU2016364976B2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
MX2022001656A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12020550745A1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
PH12016501693A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
SA520411990B1 (ar) مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين
MY186908A (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2017010630A (es) Derivado de imidazopirimidina e imidazotriazina, y composicion farmaceutica que lo comprende.
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
GR1008554B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα